凱普生物(300639.SZ): 子公司獲得一項發明專利證書
格隆匯10月23日丨凱普生物(300639.SZ)公佈,公司的全資子公司凱普醫藥和廣州凱普今日收到國家知識產權局下發的授予發明專利權通知書。發明創造名稱為一種氯喹凝膠及其製備方法和應用;申請號/專利號為201811474701.3。
該發明將水溶性納米微球載體與氯喹或氯喹衍生物聯合制備成納米微球,有效解決了氯喹的副作用和抗藥性問題;可延長藥物在治療部位的滯留時間,提高了藥物的生物利用度和治療效果,能有效治療外生殖器感染性疾病和/或其他皮膚疣類疾病。
公司已運用該發明技術開發藥品“磷酸氯喹凝膠”,目前正在開展臨牀試驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.